Travere Therapeutics Named a Finalist for the Citeline Awards Excellence in Rare Disease Drug Development

Thursday, March 28, 2024 —Travere has been named a finalist for the Citeline Awards 2024 in the category of Excellence in Rare Disease Drug Development for our work in classical homocystinuria. The award recognizes a drug development program with the largest potential impact in the rare disease space, utilizing outstanding patient-centric processes, and innovation in study conduct to overcome the various obstacles of rare disease drug development. The company’s efforts demonstrate these qualities through the innovative Phase 3 HARMONY Study design, the ongoing natural history study to understand the clinical course of the disease, work to support modernization of newborn screening. The winners will be announced in May.